173 related articles for article (PubMed ID: 2717042)
1. [Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].
Piantino P; Mosso R; Polloni R; Cerchier A; Gennaretti G; Daziano E
Minerva Med; 1989 Mar; 80(3):199-203. PubMed ID: 2717042
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
Piantino P; Arosaio E
Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
[TBL] [Abstract][Full Text] [Related]
3. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
4. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
5. The measurement of serum immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal cancer and pancreatic disease.
Satake K; Inui A; Sogabe T; Yoshii Y; Nakata B; Tanaka H; Chung YS; Hiura A; Umeyama K
Int J Pancreatol; 1988 Jul; 3(5):323-31. PubMed ID: 2459273
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
7. [Serum pancreatic enzymes and enzyme inhibitor as a tumor marker for pancreatic cancer].
Ogawa M
Rinsho Byori; 1986 Nov; 34(11):1229-35. PubMed ID: 2434691
[No Abstract] [Full Text] [Related]
8. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
Stenman UH
Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological tumor].
Shigemasa K; Hiura M; Ioka A; Yokoyama T; Nogawa T; Chiba T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Mar; 45(3):256-7. PubMed ID: 8492013
[No Abstract] [Full Text] [Related]
10. Tumor-associated trypsin inhibitor (TATI) and renal function.
Tramonti G; Ferdeghini M; Donadio C; Annichiarico C; Norpoth M; Bianchi R; Bianchi C
Kidney Int Suppl; 1997 Dec; 63():S179-81. PubMed ID: 9453997
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.
Plebani M; Basso D; Fabris C; Meggiato T; Del Favero G; Panozzo MP; Fogar P; Faggian D; Angonese C; Burlina A
Klin Wochenschr; 1989 Oct; 67(20):1029-32. PubMed ID: 2586008
[TBL] [Abstract][Full Text] [Related]
15. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
16. TATI as a biomarker.
Itkonen O; Stenman UH
Clin Chim Acta; 2014 Apr; 431():260-9. PubMed ID: 24583226
[TBL] [Abstract][Full Text] [Related]
17. [Significance of the the tumor markers, Ca-125 and tumor-associated trypsin inhibitor in patients with carcinoma of the cervix and uterus].
Ilić RS; Mihailović D
Srp Arh Celok Lek; 1992; 120(3-4):97-9. PubMed ID: 1465666
[TBL] [Abstract][Full Text] [Related]
18. [Pancreatic secretory trypsin inhibitor in urothelial cancer].
Tashiro K; Torii S; Iwamuro S; Ohishi Y; Hasegawa N; Kawashima Y; Mochizuki A; Yoshigoe H; Wada T; Machida T
Hinyokika Kiyo; 1989 Oct; 35(10):1659-63. PubMed ID: 2610172
[TBL] [Abstract][Full Text] [Related]
19. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
[TBL] [Abstract][Full Text] [Related]
20. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]